Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Retrospective, Observational Study Comparing the Efficacy and Safety of Continuous Endovenous Administration of Endostar (CE) Combined with Gemcitabine Plus Cisplatin (GP) Versus Drip Intravenous Administration of Endostar (DE) Combined with Gemcitabine Plus Cisplatin (GP) in Locally Advanced or Metastatic Lung Squamous Cell Carcinoma

Trial Profile

A Retrospective, Observational Study Comparing the Efficacy and Safety of Continuous Endovenous Administration of Endostar (CE) Combined with Gemcitabine Plus Cisplatin (GP) Versus Drip Intravenous Administration of Endostar (DE) Combined with Gemcitabine Plus Cisplatin (GP) in Locally Advanced or Metastatic Lung Squamous Cell Carcinoma

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Sep 2018

At a glance

  • Drugs Endostatin (Primary) ; Cisplatin; Gemcitabine
  • Indications Lung cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 20 Sep 2018 New trial record
    • 01 Aug 2018 Results published in the Medicine Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top